Objective: The study objective was to assess the technical and process improvement and clinical outcomes of robotic mitral valve surgery by examining the first 1000 cases performed in a tertiary care center.
Robotically assisted mitral valve surgery is the least invasive surgical approach to the mitral valve. Using a stereoscopic high-definition camera with 10-fold magnification, a dynamic retractor, and a variety of wristed instruments, the surgeon has unparalleled visualization of and access to the mitral valve. This technology enables surgeons to work through ports and small incisions on the right chest and to perform standard mitral valve procedures while sparing the patient a sternotomy. Other reported advantages for the patient include shorter postoperative stay, reduced need for blood transfusions, quicker return to full activity, and superior cosmesis. [1] [2] [3] Despite reports documenting the efficacy and safety of robotically assisted mitral valve surgery, it has not become the standard of care for managing mitral valve disease. Concerns persist regarding prolonged operative time, quality of valve repair, and hospital resource use. 4 After extensive training and preparation, our surgical team began to perform robotically assisted mitral valve surgery in 2006. We report the results of our first 1000 consecutive robotic cases, emphasizing technical and process improvement initiatives undertaken during the course of this experience, early in-hospital safety, and residual mitral regurgitation (MR).
PATIENTS AND METHODS Patients
From the first robotically assisted mitral valve surgery performed at Cleveland Clinic between January 2006 and November 2013, 1000 patients underwent primary robotically assisted mitral valve surgery. This represented 30% of 3307 patients undergoing primary isolated mitral valve surgery during that time. Patients' mean age was 56 AE 10 years (range, 18-83 years), 77% were male, and 93% were in New York Heart Association functional class I/II (Table 1 ). All patients had severe MR according to standard integrated echocardiographic criteria 5 except 2: 1 with mitral stenosis and 1 with fibroelastoma. The majority of patients had degenerative mitral valve disease (Table 2) . Among 960 patients with degenerative disease, 768 (80%) had isolated posterior leaflet prolapse on transthoracic echocardiography (TTE), 166 (17%) had bileaflet prolapse, and 24 (2.5%) had isolated anterior leaflet prolapse.
These and other data presented in this article were based on routine prospective data collection for quality and research by the Heart and Vascular Institute's Clinical Investigations group and were approved for use in research by the Cleveland Clinic Institutional Review Board, with patient consent waived.
Preoperative and Intraoperative Screening
Our preoperative screening strategy starts with routine laboratory work and chest radiography. All patients undergo coronary angiography or computed tomography (CT) angiography, and a robotic approach is not used if coronary artery bypass grafting is required. Other preoperative screening imaging includes TTE and CT scanning of the chest, abdomen, and pelvis. Intraoperative screening includes femoral ultrasound.
Transthoracic echocardiography. Several features are examined to determine whether a robotic approach is appropriate:
1. Severity of mitral annular calcification: A robotic approach is not used for patients with moderately severe or severe mitral annular calcification because robotic instrumentation is not well suited to managing it. 2. Left ventricular function: Because robotic surgery generally requires a longer period of myocardial ischemia than other approaches, it is not used for patients with important left ventricular dysfunction. 3. Severity of aortic regurgitation (AR): Presence of greater than mild AR complicates myocardial protection and can lead to ventricular distension after release of the aortic clamp. Therefore, we do not use the robotic approach in these patients.
Computed tomography scan. CT scanning of the chest, abdomen, and pelvis is used to evaluate the feasibility and safety of peripheral perfusion for cardiopulmonary bypass. A femoral artery less than 7 mm in diameter and important aortoiliac atherosclerosis constitute relative contraindications to robotic surgery. For the first 500 cases, CT scanning was obtained sporadically. Recognizing a 2% occurrence of perioperative stroke, we thereafter instituted a formal policy of obtaining such scans in all patients. Specific features of interest on the scans include presence or absence of atherosclerotic disease, femoral vessel size, unexpected vascular anatomy (eg, discontinuous inferior vena cava), and previously unrecognized pathology (eg, iliac dissection after cardiac catheterization and aortic coarctation). 6 Screening algorithm. We incorporated imaging studies after the first 500 cases into an algorithm to facilitate selection of candidates for robotically assisted surgery (Central Figure) . 
Surgical Technique
For this study, the surgical approach was considered robotic if the robot was actually placed into the surgical field. Mitral valve repair was attempted in 997 patients (99.7%), with 2 (0.2%) planned replacements and 1 (0.1%) resection of fibroelastoma. The surgical approach for patients undergoing robotic mitral valve surgery has been described (Video 1). 3, 7 Briefly, access ports are placed through the right chest, including a 40-mm minithoracotomy working port with a soft tissue retractor when a Chitwood clamp was used for aortic occlusion, and a 15-to 20-mm working port when an intra-aortic balloon was used. Right internal jugular and femoral veins are cannulated for cardiopulmonary bypass. The ascending aorta is occluded by a Chitwood transthoracic clamp (n ¼ 737, 74%) or an intra-aortic balloon (n ¼ 263, 26%). The choice rested on surgeon preference and comfort level. The heart is then arrested with 1 L of Buckberg cardioplegia readministered every 15 to 20 minutes or with a single dose of del Nido cardioplegia.
Mitral valve repair. Standard robotically assisted repair techniques 8 were used in all cases. Techniques used to correct posterior leaflet prolapse included triangular or quadrangular leaflet resection (74%), sliding repair (27%), 9 folding valvuloplasty (6.5%), 10, 11 and insertion of polytetrafluoroethylene (PTFE) chords (24%) ( Table 4 ). Anterior leaflet prolapse was treated by inserting PTFE chords (80%) and chordal transfer (8.2%). For bileaflet repair (16%), other than for repair of posterior and anterior leaflets, an edge-to-edge Alfieri stitch (8.8%) and commissuroplasty (69%) were used. All valve repairs included insertion of a flexible standard-length annuloplasty band (Cosgrove-Edwards Annuloplasty System, Edwards Lifesciences, Irvine, Calif; or Duran band, Medtronic, Minneapolis, Minn 12 ) with 2-0 polyester suture.
Tricuspid valve repair. A vertical right atriotomy was made, and repair was performed using an annuloplasty band sewn into place with interrupted 2-0 polyester suture.
Atrial fibrillation procedure. The left atrial appendage was routinely closed as part of the CryoMaze operation in a 2-layer fashion using 3-0 PTFE suture. Cryoablation was performed with a box lesion around the pulmonary veins. We then connected this lesion to the mitral valve annulus.
Adjunct pharmacologic therapy. When there was no contraindication, we administered perioperative beta-blockers to decrease the risk of atrial fibrillation, as well as postoperative aspirin. Warfarin was prescribed postoperatively for patients with recurrent or persistent atrial fibrillation.
Outcomes
Technical performance and residual mitral regurgitation. Technical performance of surgical approaches was assessed by evaluating operative variables (intraoperative transesophageal echocardiography and cardiopulmonary bypass and myocardial ischemic times). Quality of mitral valve repair was assessed by residual MR on routine predischarge TTE.
Safety. Safety was assessed by in-hospital mortality and morbidity as defined for the Society of Thoracic Surgeons National Cardiac Database (http://www.sts.org/sites/default/files/documents/STSAdultCVData SpecificationsV2_81.pdf).
Data Analysis and Presentation
All analyses were performed using SAS statistical software (SAS version 9.2; SAS Institute, Inc, Cary, NC) and R software version 3.2.2. 13 Continuous variables are summarized as mean AE standard deviation, and statistical significance of trends with experience was estimated using a linear regression model for a simple transformation of patient sequence number. Categoric variables are summarized as frequencies and percentages, and statistical significance trends with experience were estimated using a logistic regression model for a simple transformation of patient sequence number. Trends are displayed using a smoothing spline (R statistical software). 14 
RESULTS

Technical Performance
Cardiopulmonary bypass time decreased slightly after approximately 200 cases and then remained level at approximately 120 minutes on average (Figure 1, A) . Average myocardial ischemic time decreased from 110 minutes to 80 minutes over the first 200 cases and remained constant thereafter (Figure 1, B) . Although all patients had a flexible annuloplasty band inserted as part of the repair, other components of mitral valve surgical technique complexity increased as sequence number increased ( Figure E1) .
Of the 997 patients with intent to repair, 992 (99.5%) underwent mitral valve repair and 5 (0.5%) were converted to replacement. Among the 1000 patients, 20 (2%) were converted to full or partial sternotomy and 23 (2.3%) were converted to minithoracotomy. Indications for conversion included bleeding (n ¼ 6), inadequate exposure (n ¼ 5), patient anatomy (n ¼ 9), arrhythmia (n ¼ 1), unsatisfactory repair (n ¼ 14), ischemia (n ¼ 3), inadequate arrest (n ¼ 3), aortic dissection (n ¼ 1), and AR (n ¼ 1). The number of conversions to full or partial sternotomy decreased over time (Figure 2 ). 
Safety
Nine patients had intra-aortic complications or difficulties, including balloon rupture (n ¼ 5), pressure loss (n ¼ 1), malpositioning with low pressure in both arms (n ¼ 1), inadequate cardiac arrest (n ¼ 1), and coiling of the catheter (n ¼ 1). Seven patients experienced myocardial ischemia, which was treated empirically. In 6 cases, the surgeon considered the possibility of impingement on the circumflex coronary artery; this prompted revision of the annuloplasty and resulted in resolution of ischemia in all cases (2 patients were converted to a minithoracotomy; the others were treated robotically). In 1 case, the surgeon performed a sternotomy and placed a bypass graft to the right coronary artery, which resolved the ischemia.
There was a single operative death (0.1%), due to right atrial wire perforation and bleeding (Table 5 ). There was no femoral artery or vein injury requiring vascular surgical intervention in this series. Fourteen patients (1.4%) had a stroke, confirmed by both clinical examination and imaging (CT scan or magnetic resonance imaging). The source of stroke was embolic in 8 patients (57%), hypoperfusion in 2 patients (14%), and indeterminate in 4 patients (29%). By hospital discharge, 6 patients demonstrated complete neurologic recovery. Stroke occurred in 10 (2%) of the first 500 patients in whom preoperative abdominal and pelvic CT scans were not routinely available and 4 (0.8%) of the second 500 patients (Figure 3 , A, Three patients (0.3%) had phrenic nerve palsy, which resolved by 6-month follow-up in 1 patient. There were no surgical site infections (Table 5) . Twenty-five patients (2.5%) underwent reoperation for bleeding, performed through the minithoracotomy with video assistance. A single patient required a sternotomy because of hemodynamic instability; in that patient, the bleeding arose from the right atrium. A total of 189 patients (21%) experienced new-onset atrial fibrillation. Over the experience, transfusions (Figure 3 , B, Table E1 
Residual Mitral Regurgitation
Intraoperative postrepair echocardiography confirmed that 99.7% (n ¼ 989/992) of patients who received repair left the operating room with MR graded as none or mild, and predischarge echocardiography (Table E2) confirmed no MR in 832 of 935 patients (89%) and mild MR in 83 patients (8.9%), for a total of 915 of 935 patients (97.9%) with no or mild MR.
Mitral valve reoperation before hospital discharge was performed in 5 patients (0.5%) as a result of systolic anterior motion and residual or recurrent MR. One of these reoperations was performed with robotic assistance.
DISCUSSION Key Findings
This study demonstrates that algorithm-driven robotic surgery enables mitral valve repair with high early procedural success and low risks of morbidity and mortality. Although initial aortic clamp and cardiopulmonary bypass times, transfusions, and occurrence of stroke were higher, procedural efficiency and safety improved with increasing experience and application of algorithm-driven patient selection. Technical and process improvement and early inhospital safety were achieved in part by strategically introducing robotically assisted mitral valve surgery by a single surgeon highly experienced in mitral repair. Subsequently, another experienced mitral valve surgeon was introduced, and recently, a third. Improvement was also driven by a conservative approach that led to the screening algorithm presented in Figure E2 and the Central Figure and a liberal approach to conversion from robotic to conventional incisions. This permitted surgeons to progressively gain experience without compromising procedural success, effectiveness, or patient safety.
Current Guidelines
Robotically assisted mitral valve surgery was introduced in the late 1990s to enhance mitral valve operations by improving technical precision and decreasing procedural invasiveness. The combination of highresolution 3-dimensional imaging and maneuverability of endoscopic instruments facilitates complete mitral valve repair for nearly all patients with degenerative disease. American College of Cardiology/American Heart Association guidelines provide a Class IIb recommendation: ''.MV repair is reasonable in asymptomatic patients with chronic severe primary MR (stage C1) with preserved left ventricular function (left ventricular ejection fraction >60% and left ventricular end-systolic diameter <40 mm) in whom the likelihood of a successful and durable repair without residual MR is >95% with an expected mortality rate of <1%.''.
15 Robotically assisted mitral valve repair satisfies these criteria and therefore represents a particularly appealing approach for Figure 2 . B, Transfusion. Format is as in Figure 2 . C, Median intensive care unit length of stay. Solid line represents the smoothing spline curve for the median, and filled circles represent the median for every 50 patients. D, Median postoperative length of stay. Solid line represents the smoothing spline curve for the median, and filled circles represent the median for every 50 patients. ICU, Intensive care unit.
asymptomatic patients with severe MR caused by degenerative disease.
Despite favorable results with robotically assisted mitral valve surgery, perceived and real concerns about procedural complexity and cost, as well as challenging patient characteristics (eg, mitral annular calcification and aortoiliac atherosclerosis), have limited its acceptance. [16] [17] [18] Our algorithm (Table 3 , Figure E2 , and Central Figure) directs patients with unfavorable features to a nonrobotic approach, which generally provides a safer option for mitral valve surgery. Although it is possible to work around each of these limitations and still use the surgical robot, we believe that a conservative approach is most appropriate to optimize patient outcomes.
Technical Performance
Over the course of this 1000-patient experience, operative technique evolved, facilitating valve repair and reducing myocardial ischemic time. We believe that surgeon experience and simplified techniques to correct leaflet prolapse (inserting artificial chords rather than chordal transfer and triangular resection rather than extensive resection), coupled with a running suture technique to place the annuloplasty band, reduced aortic clamp times. 12, 19 However, the long-term results of a running suture technique for annuloplasty insertion have not been documented.
Streamlined techniques and new instrumentation, combined with increased surgeon experience and better understanding of patient candidacy, improved results over time. Conversion to partial and complete sternotomy was higher than expected. However, with increased experience, in the last 200 cases it declined to 1%.
Residual Mitral Regurgitation
Mitral valve repair was achieved in 99.5% of patients for whom it was intended, and 97.9% of these had no or only mild MR at discharge. These excellent results in a large series, similar to those of others, 17, 18, 20, 21 emphasize that the results are reproducible. Although our study reports only inhospital outcomes, others performing robotically assisted mitral valve repair have documented 5-year survival, freedom from recurrent MR, and freedom from reoperation of 99.5%, 94.6%, and 97.7%, respectively. 17 Studies of long-term results of robotically assisted mitral valve repair demonstrate that survival and durability are similar to those obtained with nonrobotic approaches.
3,17,18
Safety
Safety is contingent on conservative identification of appropriate candidates, procedural technique, and willingness to convert without hesitation from the robotic approach to a conventional approach if it appears to compromise valve repair or risk adverse outcomes. Several studies, including our own, demonstrate the safety of robotically assisted mitral valve surgery. 3, 17, 18, 20, 21 Compared with nonrobotic approaches, it has been associated with lower in-hospital mortality, less blood loss, fewer incisional infections, shorter postoperative lengths of stay, more rapid return to normal activity, and superior cosmesis. 3, [22] [23] [24] In our previous study of 261 patients undergoing robotically assisted mitral valve repair of degenerative posterior leaflet disease, quality of valve repair was similar in propensity-matched cohorts to that performed through a full sternotomy, partial sternotomy, or anterior thoracotomy, but less postoperative atrial fibrillation and fewer pleural effusions contributed to shorter postoperative stays. 3 Retrograde femoral perfusion and the attendant risk of stroke remain an important concern. A recent report using the Society of Thoracic Surgeons' database documented 2-fold higher occurrence of neurologic complications with less-invasive mitral valve surgery that included femoral artery perfusion. 25 However, others contend there is no convincing evidence that retrograde perfusion per se during less-invasive mitral valve surgery increases the risk of stroke. 26 We believe that retrograde embolization of atheromatous material, and embolization of air and debris from the left atrium, are the most likely causes; placing a clamp on an atherosclerotic aorta is another potential source of emboli. Preoperative CT scanning identifies patients at risk, enabling use of safer perfusion strategies. The latter might include axillary artery cannulation for cardiopulmonary bypass. 27 
Study Limitations
This study has limitations inherent to all single-institution clinical studies. We did not assess cost or resource use; however, we and others have addressed those aspects of robotic mitral surgery in previous reports. 13, 28 Stroke remains an important concern. This study traces the evolution of robotic mitral surgery at our institution and thus includes several different surgical techniques as these evolved.
CONCLUSIONS
Successful and safe mitral valve repair is achievable with a variety of incisional approaches, including full sternotomy, partial sternotomy, right thoracotomy, and robotically assisted right chest approaches. 3 In all cases, the surgeon's skill and experience, combined with algorithm-driven patient selection, high volume, and an exceptional care team, dictate the ultimate result. Robotically assisted mitral valve repair is an effective and safe approach for correcting MR, with low operative mortality and morbidity and approximately 100% successful valve repair. Results improve with experience, and algorithm-driven patient selection further enhances procedural efficiency and clinical outcomes. Robotically assisted mitral valve surgery sets a standard for comparison with emerging percutaneous mitral valve interventions.
in the first place? After this large experience, have your perspectives changed on the relative value of robotics versus other approaches, such as sternotomy or port access?
Dr Gillinov (Cleveland, Ohio). First, I should give credit to Tom Mihaljevic, because he was the first surgeon to perform robotic mitral valve surgery at Cleveland Clinic. He deserves a great deal of credit for getting this going.
The main reason that we started the robotic program was to be able to offer a broad range of options to the person who has mitral valve disease. Rather than a one size fits all approach, we wanted to be able to look at each patient and determine in our hands what will be best: robotic, right thoracotomy, partial sternotomy, or full sternotomy. Our goal was to be able to tailor the mitral operation to fit the patient.
Dr Guy. So if robotic approaches are as beneficial as your report would suggest that they are, why be so restrictive in whom you perform the procedure? For instance, reasonable alternative cannulation strategies exist for femoral arteries less than 7 mm. You mentioned aortoiliac disease as a contraindication. Axillary cannulation is one option for these patients. Also, any mitral valve patients with mitral valve disease have pulmonary hypertension, need a replacement, have depressed left ventricular function, and have had prior cardiac surgery and pathologies other than prolapse, which was largely disease treated in your series. Why exclude so many patients if you have confidence in the technique? Dr Gillinov. I think now that we have looked at our results, you are right, we have confidence in the technique and are beginning to extend our indications. We will use axillary cannulation for the small femorals or for aortoiliac atherosclerosis. We haven't yet tackled reoperations with vigor, but we are looking at those.
The one thing, though, that is really off-putting to me with the robot is the person who has aortic insufficiency that is more than 1+. I would still stay away from aortic insufficiency, because when you take the clamp off, if the ventricle distends, you could be in big trouble.
Dr Guy. Excellent. On the basis of the lessons learned from this large experience, where do you think robotic mitral valve surgery fits into the future of mitral valve intervention given the relative tsunami of catheter devices for the treatment of mitral valve disease that has set upon our shores? Dr Gillinov. Yes, I see them when I look out at the sea. They are coming in; they are almost here. I think the robotic approach is here to stay because it offers the ability to do the same complete repair with all of the maneuvers you might use through a sternotomy but via a truly minimally invasive approach. Right now I don't see any single transcatheter repair device that will be able to replicate this. I think in your patients aged 50, 60, 70 years, or even 80 years, if that person has mitral valve prolapse, we want to do the best operation we can. So I think it is here for a good long while.
Dr S. Hasan (Karachi, Pakistan). Congratulations, Marc. A wonderful series and well presented. Is there a distinct advantage to using the robot over a minithoracotomy approach?
Dr Gillinov. They are almost the same operation, truthfully, and I think the robot is one way to do a nonsternotomy or sternal-sparing approach. I don't think there are any data to suggest one is necessarily better than the other, though.
Dr V. Badhwar (Morgantown, WVa Dr Gillinov. We use the Chitwood transthoracic clamp because it is 100% reliable; you always get occlusion of the aorta. With the EndoClamp, the balloon is placed transfemorally; it will occasionally migrate, sometimes you don't get good occlusion from the get-go, and then occasionally you will have trouble with cardioplegia delivery if the port that enables the cardioplegia to come out is against the wall. So it is kind of finicky, in addition to costing more.
That said, if you are going to do a redo, it offers distinct advantages, because you don't have to dissect out the aorta. But the Chitwood clamp is our go-to because it is easy and it is reliable. Dr D. Mazzitelli (Munich, Germany). Did you use the last generation of robotic from the beginning of this series, I mean with the fourth arm, the 3-dimensional camera was used from the beginning in this series? Dr Gillinov. In this series, we used the Si for most cases. We have a Xi on the way, so we will see how we do with that.
Dr Mazzitelli. I think this significantly helps to improve the results with the new generation.
Dr Gillinov. I think the Xi is wonderful. 
